Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767339 | 0.92 | HSPD1 (0.40) | HSPD1HSPE1KMT2AMEN1HTT | |
| SCHEMBL4766006 | 0.89 | PDE4A (0.44) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4762307 | 0.85 | DCTPP1 (0.44) | KMT2AMEN1HTTSMN1; SMN2POLB | |
| SCHEMBL4766297 | 0.83 | HSPD1 (0.36) | HSPD1HSPE1KMT2AMEN1PARG | |
| SCHEMBL4762645 | 0.82 | PARG (0.45) | HSPD1HSPE1KMT2AMEN1HTT | |
| SCHEMBL4762551 | 0.81 | PDE5A (0.40) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4863899 | 0.81 | PARG (0.38) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4769688 | 0.81 | PDE4A (0.40) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4771305 | 0.80 | HTT (0.44) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4767937 | 0.79 | PDE4A (0.46) | PDE4AHSPD1HSPE1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE4A 182/4885HSPD1 1658/4885HSPE1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.